Lille (France), Boston (Massachusetts, United States), May 7, 2015 - GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its turnover for the period January 1st to March 31, 2015 and its cash situation as of March 31, 2015.
The turnover of first quarter of 2015, resulting mainly from the Company's research collaboration with Sanofi, amounted to €0.15 million against €1.13 million for the same period in 2014 (including €1 million milestone payment through the Company's research collaboration with Sanofi).
As of March 31, 2015, the cash, cash equivalents, and current financial instruments of the Company amounted to €69.46 million. The cash position as of March 31, 2014 amounted to €20.91 million.
The first quarter of 2015 was principally marked by the results of the GOLDEN-505 study demonstrating a strong histological anti-NASH activity, a very good cardioprotective profile and an excellent safety.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.
GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that has completed a positive Phase 2b study in NASH and is currently launching a Phase 3 study. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 90 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Help employers find you! Check out all the jobs and post your resume.
The turnover of first quarter of 2015, resulting mainly from the Company's research collaboration with Sanofi, amounted to €0.15 million against €1.13 million for the same period in 2014 (including €1 million milestone payment through the Company's research collaboration with Sanofi).
As of March 31, 2015, the cash, cash equivalents, and current financial instruments of the Company amounted to €69.46 million. The cash position as of March 31, 2014 amounted to €20.91 million.
The first quarter of 2015 was principally marked by the results of the GOLDEN-505 study demonstrating a strong histological anti-NASH activity, a very good cardioprotective profile and an excellent safety.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.
GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that has completed a positive Phase 2b study in NASH and is currently launching a Phase 3 study. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 90 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Help employers find you! Check out all the jobs and post your resume.
